** BioAge Labs BIOA.O shares down 0.3% before the bell at $20.06 after co raises more equity than planned

** Emeryville, California-based biopharma late Weds sold ~5.9 mln shares, about 16% of total outstanding, at $19.50 for $115 mln gross proceeds

** Offering price represents 3.1% discount to stock's last close

** BIOA shares on Weds finished down 5.6% after co late Tues unveiled $75 mln offering

** Co intends to use net offering proceeds to fund research, clinical development and manufacturing of its product candidates, including lead candidate BGE-102, a small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, among other purposes

** Goldman Sachs, Piper Sandler and Citigroup joint bookrunners

** Through Weds, BIOA shares up 52% to begin 2026 and have more than tripled over the past three months

** 1 analyst rates the stock "strong buy", 3 rate "hold"; PTs are $9, $12 and $15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))